CDKN2A and malignant mesothelioma: Alteration of the CDKN2A locus in human malignant mesothelioma has been reported with inactivation of p16 in more than a half of mesothelioma patients [9] and, in more recent studies, with hypermethylation and silencing of p19 in 44% of patients [39].